Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Immunocore Holdings plcNASDAQ: IMCR

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $12.95M rose 157.8% year over year, ahead of the +28.8% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -20.5% a year.

Context

  • Net income amounted to 8.9% of revenue in FY2025, down 11.7 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 11 analysts of $2.53M (+109.6%) for the fiscal year ending Dec 2026, a step up from the -48.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.95M+143.1% QoQ
Last fiscal yearDec 2025
-$26.42M-48.3% YoY
LTMMar 2026
-$27.59M+28.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+157.8%+105.0%-52.8 pp
1 year-48.3%+109.6%+157.9 pp
3-year CAGR-20.5%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

Mixed currencies · from the cash flow

Latest · FY2025
(26.42M) USD
Year-over-year change
+48.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +28.8% is the 7th highest of 10, against a peer median of +47.3%.
  • Net income amounts to 7.2% of revenue for IMCR, versus a peer median of 461.4%.
IMCR Competitors
Net Income for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.71B EUR+348.2%—64.7%
IBRXImmunityBio, Inc.LTM Sep 2026$1.11B USD+218.3%-5.5%607.8%
RCUSArcus Biosciences, Inc.LTM Jun 2026$460M USD+54.4%+9.8%393.2%
IMTXImmatics N.V.LTM Mar 2026€217.14M EUR+906.0%—582.2%
JANXJanux Therapeutics, Inc.LTM Mar 2026$114.48M USD+47.3%+21.7%529.7%
XNCRXencor, Inc.LTM Jun 2026$71.19M USD-60.8%+18.5%67.8%
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
IMMPImmutep LimitedFY2025A$61.43M AUD+43.8%+24.0%1218.0%
IPHAInnate Pharma S.A.FY2025€49.18M EUR-0.6%-5.4%1764.5%
CGENCompugen Ltd.LTM Dec 2025$35.34M USD——48.6%
IMCRImmunocore Holdings plcLTM Mar 2026$27.59M USD+28.8%-20.5%7.2%
Peer median (excluding IMCR) —+47.3%+9.8%461.4%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(180.03M)(52.54M)(34.32M)(51.09M)(26.42M)
Depreciation & Amortization7.59M5.34M3.24M4.2M2.43M
Deferred Income Tax(12.69M)(3.53M)0011M
Stock-Based Compensation48.89M32.89M25.69M34.19M0
Change in Working Capital(21.96M)(24.17M)4.58M45.13M(6.92M)
Accounts Receivables(4.86M)(26.26M)(14.14M)(12.35M)(5.46M)
Inventory00000
Accounts Payables1.47M4.91M2.08M7.27M(1.83M)
Other Working Capital(18.57M)(2.81M)16.64M50.21M366K
Other Non-Cash Items15.09M(7.19M)3.14M(6.38M)11.94M
Operating Cash Flow(143.11M)(49.21M)2.33M26.06M(7.97M)
Capital Expenditures(1.39M)(2.2M)(4.29M)(5.17M)(3.23M)
Acquisitions (Net)00000
Purchases of Investments000(350M)(22.32M)
Sales of Investments000013.39M
Other Investing Activities106K6K(925.46K)44K0
Investing Cash Flow(1.28M)(2.2M)(4.29M)(355.13M)(12.16M)
Debt Repayment000352.5M0
Common Stock Issued286.89M139.52M06.8M9.2M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.3M5.93M27.18M(15.42M)0
Financing Cash Flow288.19M145.44M27.18M343.88M9.2M
Effect of Forex Changes625K(12.65M)6.56M(1.71M)19.81M
Net Change in Cash144.42M81.39M31.78M13.11M8.89M
Free Cash Flow(144.49M)(51.41M)(1.97M)20.89M(11.2M)

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.